Goldman Sachs Group, Inc. (The) Analysts Give Morphosys AG (MOR) a €72.00 Price Target

Goldman Sachs Group, Inc. (The) set a €72.00 ($84.71) price objective on Morphosys AG (ETR:MOR) in a research report sent to investors on Wednesday, November 8th. The firm currently has a neutral rating on the stock.

Several other analysts have also recently commented on the company. Commerzbank Ag set a €76.00 ($89.41) target price on Morphosys AG and gave the stock a buy rating in a research report on Thursday, August 31st. Deutsche Bank AG set a €90.00 ($105.88) target price on Morphosys AG and gave the stock a buy rating in a research report on Thursday, September 7th. Berenberg Bank set a €68.00 ($80.00) target price on Morphosys AG and gave the stock a buy rating in a research report on Friday, July 14th. Independent Research GmbH set a €77.00 ($90.59) target price on Morphosys AG and gave the stock a buy rating in a research report on Thursday, September 7th. Finally, J P Morgan Chase & Co reaffirmed a buy rating and issued a target price on shares of Morphosys AG in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of €81.25 ($95.59).

Shares of Morphosys AG (ETR:MOR) opened at €81.93 ($96.39) on Wednesday. Morphosys AG has a 12-month low of €40.10 ($47.18) and a 12-month high of €82.20 ($96.71).

COPYRIGHT VIOLATION WARNING: “Goldman Sachs Group, Inc. (The) Analysts Give Morphosys AG (MOR) a €72.00 Price Target” was published by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://baseballnewssource.com/markets/morphosys-ag-mor-given-a-72-00-price-target-at-goldman-sachs-group-inc-the/1765824.html.

Morphosys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for Morphosys AG (ETR:MOR)

Receive News & Ratings for Morphosys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphosys AG and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.